What is the debt of Immunitybio this year?
Immunitybio has a debt level of 572.97 USD this year.
Immunitybio Debt 2024
Immunitybio Debt
572.97 USD
Ticker
IBRX
ISIN
US45256X1037
WKN
A2QQ2E
In 2024, Immunitybio's total debt was 572.97 USD, a 0.5% change from the 570.1 USD total debt recorded in the previous year.
Immunitybio Aktienanalyse
What does Immunitybio do?
Translate this as near as possible to English. ImmunityBio Inc is a biotechnology company specializing in innovative methods to combat cancer and other serious diseases. The company was founded in 2015 by esteemed biotech entrepreneur and scientist, Dr. Patrick Soon-Shiong. The idea behind ImmunityBio was to create a company focused on developing advanced immunotherapies that involve the human immune system in the fight against cancer. The business model is based on several business units, including research and development, diagnostics, and therapeutics. In recent years, the company has expanded through a series of significant acquisitions and mergers, including CytRx Corporation, NantWorks LLC, and NantKwest Inc. Together, these mergers have expanded and united the resources and expertise of ImmunityBio to achieve new advancements in oncology. ImmunityBio has also developed a variety of products focused on strengthening the immune system, including its leading drug, INT-001, intended for the treatment of lung, pancreatic, breast, stomach, and colorectal cancer. The company has also developed diagnostic products, such as the ImmuneMap™ test, which analyzes the patient's immune profile and can contribute to better combinations of existing immunotherapies. Another business unit is the service department, which focuses on providing services related to precision medicine. ImmunityBio offers a wide range of personalized drugs and services to help provide patients with better and more effective treatment. The company also has an extensive pipeline of immunotherapies for various indications, including several clinical trials for the treatment of lung cancer, pancreatic cancer, and breast cancer. The portfolio includes both single agents and combination therapies, which the company will introduce after a rigorous phase 1 study. Overall, ImmunityBio has an ambitious goal of being a leading player in the innovation of immunotherapies. Through a multidisciplinary approach to the discovery and development of new treatments, ImmunityBio is working to defeat cancer by strengthening the immune system and improving the quality of life for patients worldwide. Immunitybio ist eines der beliebtesten Unternehmen auf Eulerpool.com.Debt Details
Understanding Immunitybio's Debt Structure
Immunitybio's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.
Year-to-Year Comparison
Analyzing Immunitybio's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.
Impact on Investments
Investors pay close attention to Immunitybio’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.
Interpreting Debt Fluctuations
Shifts in Immunitybio’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.
Frequently Asked Questions about Immunitybio Stock
What was the debt of Immunitybio compared to the previous year?
The debt of Immunitybio has increased by 0.5% compared to the previous year increased.
What are the consequences of high debt for investors in Immunitybio?
High debt can pose a risk for investors of Immunitybio, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.
What are the consequences of low debt for investors of Immunitybio?
Low debt means that Immunitybio has a strong financial position and is able to fulfill its obligations without overburdening its finances.
How does an increase in debt from Immunitybio affect the company?
An increase in debt of Immunitybio can adversely affect the financial condition of the company and result in a higher burden on its finances.
How does a reduction of debt of Immunitybio affect the company?
A reduction in debt of Immunitybio can strengthen the company's financial position and improve its ability to meet its financial obligations.
What are some factors that influence the debt of Immunitybio?
Some factors that can influence the debt of Immunitybio include investments, acquisitions, operating costs, and revenue development.
Why are the debts of Immunitybio so important for investors?
The debts of Immunitybio are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.
What strategic measures can Immunitybio take to change the debt?
To change the debt, Immunitybio can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.
How much dividend does Immunitybio pay?
Over the past 12 months, Immunitybio paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Immunitybio is expected to pay a dividend of 0 USD.
What is the dividend yield of Immunitybio?
The current dividend yield of Immunitybio is .
When does Immunitybio pay dividends?
Immunitybio pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Immunitybio?
Immunitybio paid dividends every year for the past 0 years.
What is the dividend of Immunitybio?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Immunitybio located?
Immunitybio is assigned to the 'Health' sector.
Wann musste ich die Aktien von Immunitybio kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Immunitybio from 6/16/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/16/2024.
When did Immunitybio pay the last dividend?
The last dividend was paid out on 6/16/2024.
What was the dividend of Immunitybio in the year 2023?
In the year 2023, Immunitybio distributed 0 USD as dividends.
In which currency does Immunitybio pay out the dividend?
The dividends of Immunitybio are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Immunitybio
Our stock analysis for Immunitybio Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immunitybio Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
